Amgen v Sanofi: Scotus grapples with enablement

The showdown between Amgen and Sanofi concerning the proper test for enablement under Section 112 of the US Patent Act has finally taken place at the US Supreme Court.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

GLP-1 patents and Africa: The COVID-19 lessons we still have not learned

Cooley Asia transactions duo make rival firm move

Insilico lands potential $2.5bn AI biotech partnership

‘Blatant imitation’: Indian court blocks copycat pharma branding

US life sciences damages averaged $33.5m between 2019-2025

Quantum and photonics tech licensing expert joins EIP

Court upholds $83m sequencing verdict and sets royalty rate

Amgen and subsidiary dealt $20m blow over rodent antibody tech

Amgen v Sanofi: Scotus grapples with enablement

More on this story

Editor's picks

Editor's picks

More features